US Patent 7332481 Thrombopoietin mimetics
Patent 7332481 was granted and assigned to Smithkline Beecham Limited on February, 2008 by the United States Patent and Trademark Office.
All edits
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+382 characters)
Article
Patent abstract
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07332481 Thrombopoietin mimetics US Patent 7332481 Thrombopoietin mimetics
Infobox
Patent Number
0733248100
Patent Number
733248100
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
073324810
Date of Patent
February 19, 2008
0Patent Application Number
116202600
Date Filed
January 5, 2007
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
073324810
Date of Patent
February 19, 2008
0Patent Application Number
116202600
Date Filed
January 5, 2007
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 23 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07332481 Thrombopoietin mimetics
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07332481
Date of patent
February 19, 2008
Patent application number
11620260
Date Filed
January 5, 2007
Patent primary examiner
Find more entities like US Patent 7332481 Thrombopoietin mimetics
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.